-
Something wrong with this record ?
Distinct modulation of telomere length in two T-lymphoblastic leukemia cell lines by cytotoxic nucleoside phosphonates PMEG and PMEDAP
M. Hájek, V. Cvilink, I. Votruba, A. Holý, H. Mertlíková-Kaiserová,
Language English Country Netherlands
Document type Journal Article, Research Support, Non-U.S. Gov't
- MeSH
- Adenine analogs & derivatives pharmacology MeSH
- Cell Culture Techniques MeSH
- Time Factors MeSH
- Electrophoresis, Polyacrylamide Gel MeSH
- Guanine analogs & derivatives pharmacology MeSH
- In Situ Hybridization, Fluorescence MeSH
- Humans MeSH
- Cell Line, Tumor MeSH
- Organophosphorus Compounds pharmacology MeSH
- Reverse Transcriptase Polymerase Chain Reaction MeSH
- Antineoplastic Agents pharmacology MeSH
- Proto-Oncogene Proteins c-myc biosynthesis MeSH
- RNA metabolism MeSH
- Telomerase antagonists & inhibitors biosynthesis MeSH
- Telomere drug effects MeSH
- Dose-Response Relationship, Drug MeSH
- Check Tag
- Humans MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
We have previously shown that PMEG diphosphate (PMEGpp) and PMEDAP diphosphate (PMEDAPpp) inhibit the enzymatic activity of human telomerase in a cell-free assay. Here, we investigated the ability of PMEG and PMEDAP to induce telomere shortening and telomerase inhibition at both transcriptional and activity level in T-lymphoblastic leukemia cells CCRF-CEM and MOLT-4. At defined time points (3days and 9weeks), the telomerase activity and relative levels of hTERT and c-myc mRNA were determined using real-time RT-PCR. Telomere length was measured by the flow-FISH method. Both PMEDAP and PMEG induced telomere shortening in CCRF-CEM cells after 9weeks of exposure by 50% and 20%, respectively, without major impairment of telomerase activity. The effect of the tested compounds on telomere length in MOLT-4 cells was the opposite, with telomere elongation by 50% and 40% after 9-week treatment with PMEDAP and PMEG, respectively. At this time point, telomerase activity in MOLT-4 cells appeared to be slightly higher than that of CCRF-CEM cells, nevertheless no correlation between telomerase activity and telomere length was found. Both compounds down-regulated the expression of hTERT and c-myc mRNA in CCRF-CEM and MOLT-4 cells at 72h in a concentration-dependent manner while prolonged exposure to PMEG or PMEDAP for 9weeks had weaker effects. In conclusion, PMEDAP and PMEG are able to modulate telomere length in leukemic cells and this effect is cell-type specific. It is neither due to direct telomerase inhibition nor impairment of hTERT expression and it is likely to be telomerase-independent.
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc12026285
- 003
- CZ-PrNML
- 005
- 20121207101606.0
- 007
- ta
- 008
- 120817e20100622ne f 000 0#eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.ejphar.2010.06.006 $2 doi
- 035 __
- $a (PubMed)20599933
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a ne
- 100 1_
- $a Hájek, Miroslav $u Institute of Organic Chemistry and Biochemistry, Academy of Sciences of the Czech Republic.
- 245 10
- $a Distinct modulation of telomere length in two T-lymphoblastic leukemia cell lines by cytotoxic nucleoside phosphonates PMEG and PMEDAP / $c M. Hájek, V. Cvilink, I. Votruba, A. Holý, H. Mertlíková-Kaiserová,
- 520 9_
- $a We have previously shown that PMEG diphosphate (PMEGpp) and PMEDAP diphosphate (PMEDAPpp) inhibit the enzymatic activity of human telomerase in a cell-free assay. Here, we investigated the ability of PMEG and PMEDAP to induce telomere shortening and telomerase inhibition at both transcriptional and activity level in T-lymphoblastic leukemia cells CCRF-CEM and MOLT-4. At defined time points (3days and 9weeks), the telomerase activity and relative levels of hTERT and c-myc mRNA were determined using real-time RT-PCR. Telomere length was measured by the flow-FISH method. Both PMEDAP and PMEG induced telomere shortening in CCRF-CEM cells after 9weeks of exposure by 50% and 20%, respectively, without major impairment of telomerase activity. The effect of the tested compounds on telomere length in MOLT-4 cells was the opposite, with telomere elongation by 50% and 40% after 9-week treatment with PMEDAP and PMEG, respectively. At this time point, telomerase activity in MOLT-4 cells appeared to be slightly higher than that of CCRF-CEM cells, nevertheless no correlation between telomerase activity and telomere length was found. Both compounds down-regulated the expression of hTERT and c-myc mRNA in CCRF-CEM and MOLT-4 cells at 72h in a concentration-dependent manner while prolonged exposure to PMEG or PMEDAP for 9weeks had weaker effects. In conclusion, PMEDAP and PMEG are able to modulate telomere length in leukemic cells and this effect is cell-type specific. It is neither due to direct telomerase inhibition nor impairment of hTERT expression and it is likely to be telomerase-independent.
- 650 _2
- $a adenin $x analogy a deriváty $x farmakologie $7 D000225
- 650 _2
- $a protinádorové látky $x farmakologie $7 D000970
- 650 _2
- $a buněčné kultury $7 D018929
- 650 _2
- $a nádorové buněčné linie $7 D045744
- 650 _2
- $a vztah mezi dávkou a účinkem léčiva $7 D004305
- 650 _2
- $a elektroforéza v polyakrylamidovém gelu $7 D004591
- 650 _2
- $a guanin $x analogy a deriváty $x farmakologie $7 D006147
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a hybridizace in situ fluorescenční $7 D017404
- 650 _2
- $a organofosforové sloučeniny $x farmakologie $7 D009943
- 650 _2
- $a protoonkogenní proteiny c-myc $x biosyntéza $7 D016271
- 650 _2
- $a RNA $x metabolismus $7 D012313
- 650 _2
- $a polymerázová řetězová reakce s reverzní transkripcí $7 D020133
- 650 _2
- $a telomerasa $x antagonisté a inhibitory $x biosyntéza $7 D019098
- 650 _2
- $a telomery $x účinky léků $7 D016615
- 650 _2
- $a časové faktory $7 D013997
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Cvilink, Viktor
- 700 1_
- $a Votruba, Ivan
- 700 1_
- $a Holý, Antonín
- 700 1_
- $a Mertlíková-Kaiserová, Helena
- 773 0_
- $w MED00001641 $t European journal of pharmacology $x 1879-0712 $g Roč. 643, č. 1 (20100622), s. 6-12
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/20599933 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y m
- 990 __
- $a 20120817 $b ABA008
- 991 __
- $a 20121207101640 $b ABA008
- 999 __
- $a ok $b bmc $g 948327 $s 783631
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2010 $b 643 $c 1 $d 6-12 $e 20100622 $i 1879-0712 $m European journal of pharmacology $n Eur J Pharmacol $x MED00001641
- LZP __
- $a Pubmed-20120817/10/04